HUT65623A - Process for preparing polycyclic guanine derivatives and pharmaceutical preparations containing them - Google Patents

Process for preparing polycyclic guanine derivatives and pharmaceutical preparations containing them Download PDF

Info

Publication number
HUT65623A
HUT65623A HU9204032A HU403292A HUT65623A HU T65623 A HUT65623 A HU T65623A HU 9204032 A HU9204032 A HU 9204032A HU 403292 A HU403292 A HU 403292A HU T65623 A HUT65623 A HU T65623A
Authority
HU
Hungary
Prior art keywords
benzyl
imidazo
purin
dimethyl
methyl
Prior art date
Application number
HU9204032A
Other languages
English (en)
Hungarian (hu)
Other versions
HU9204032D0 (en
Inventor
Bernard R Neustadt
Neil A Lindo
Brian A Mckittrick
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering Corp filed Critical Schering Corp
Publication of HU9204032D0 publication Critical patent/HU9204032D0/hu
Publication of HUT65623A publication Critical patent/HUT65623A/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/12—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains three hetero rings
    • C07D487/14—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Filtering Materials (AREA)
HU9204032A 1990-06-21 1991-06-20 Process for preparing polycyclic guanine derivatives and pharmaceutical preparations containing them HUT65623A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US54156890A 1990-06-21 1990-06-21

Publications (2)

Publication Number Publication Date
HU9204032D0 HU9204032D0 (en) 1993-03-29
HUT65623A true HUT65623A (en) 1994-07-28

Family

ID=24160139

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9204032A HUT65623A (en) 1990-06-21 1991-06-20 Process for preparing polycyclic guanine derivatives and pharmaceutical preparations containing them

Country Status (21)

Country Link
US (1) US5393755A (OSRAM)
EP (1) EP0538332B1 (OSRAM)
JP (1) JPH0747589B2 (OSRAM)
KR (1) KR960004532B1 (OSRAM)
AT (1) ATE155786T1 (OSRAM)
AU (1) AU651607B2 (OSRAM)
CA (1) CA2085733C (OSRAM)
CZ (1) CZ281920B6 (OSRAM)
DE (1) DE69126980T2 (OSRAM)
FI (1) FI925731A7 (OSRAM)
HU (1) HUT65623A (OSRAM)
IE (1) IE912126A1 (OSRAM)
IL (1) IL98559A0 (OSRAM)
NO (1) NO924940D0 (OSRAM)
NZ (1) NZ238609A (OSRAM)
OA (1) OA09723A (OSRAM)
PL (1) PL169481B1 (OSRAM)
RU (1) RU2080322C1 (OSRAM)
TW (1) TW197441B (OSRAM)
WO (1) WO1991019717A1 (OSRAM)
ZA (1) ZA914727B (OSRAM)

Families Citing this family (78)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1118600A (zh) * 1993-02-26 1996-03-13 先灵公司 2-苄基-多环鸟嘌呤衍生物以及制备它们的方法
US5929046A (en) * 1994-06-08 1999-07-27 Cancer Research Campaign Technology Limited Pyrimidine and purine derivatives and their use in treating tumour cells
US5661153A (en) * 1994-07-19 1997-08-26 Japan Energy Corporation 1-arylpyrimidine derivatives and pharmaceutical use thereof
US5824683A (en) * 1995-11-28 1998-10-20 Schering Corporation 2'- 4'-halo- 1,1'-biphenyl!-4-yl!methyl!-5'-methyl-spiro cyclopentane-1,7' (8'H)- 3H! imidazo 2,1-b!purin!-4' (5'H)-ones
ZA969888B (en) * 1995-11-28 1997-05-26 Schering Corp 2'-[[4'-halo-[1,1-biphenyl]-4-yl]methyl]-5'-methyl-spiro[cyclopentane-1,7'(8'H)-[3H]imidazo[2,1-b]purin]-4'(5'H)-ones
US5858694A (en) * 1997-05-30 1999-01-12 Cell Pathways, Inc. Method for identifying compounds for inhibition of cancerous lesions
CA2238283C (en) 1997-05-30 2002-08-20 Cell Pathways, Inc. Method for identifying compounds for inhibition of neoplastic lesions, pharmaceutical compositions from such compounds and uses of such compounds and compositions for treating neoplastic lesions
US6410584B1 (en) * 1998-01-14 2002-06-25 Cell Pathways, Inc. Method for inhibiting neoplastic cells with indole derivatives
US6200771B1 (en) 1998-10-15 2001-03-13 Cell Pathways, Inc. Method of using a novel phosphodiesterase in pharmaceutical screeing to identify compounds for treatment of neoplasia
US6130053A (en) * 1999-08-03 2000-10-10 Cell Pathways, Inc. Method for selecting compounds for inhibition of neoplastic lesions
US6133271A (en) * 1998-11-19 2000-10-17 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives
US6187779B1 (en) 1998-11-20 2001-02-13 Cell Pathways, Inc. Method for inhibiting neoplastic cells and related conditions by exposure to 2,8-disubstituted quinazoline derivatives
US6369092B1 (en) 1998-11-23 2002-04-09 Cell Pathways, Inc. Method for treating neoplasia by exposure to substituted benzimidazole derivatives
US6486155B1 (en) 1998-11-24 2002-11-26 Cell Pathways Inc Method of inhibiting neoplastic cells with isoquinoline derivatives
US6077842A (en) * 1998-11-24 2000-06-20 Cell Pathways, Inc. Method of inhibiting neoplastic cells with pyrazolopyridylpyridazinone derivatives
US6034099A (en) * 1998-11-24 2000-03-07 Cell Pathways, Inc. Method for inhibiting neoplastic lesions by administering 4-(arylmethylene)- 2, 3- dihydro-pyrazol-3-ones
US6025394A (en) 1999-01-29 2000-02-15 Cell Pathways, Inc. Method for treating patients with acne by administering substituted sulfonyl indenyl acetic acids, amides and alcohols
US6020379A (en) * 1999-02-19 2000-02-01 Cell Pathways, Inc. Position 7 substituted indenyl-3-acetic acid derivatives and amides thereof for the treatment of neoplasia
ES2166270B1 (es) * 1999-07-27 2003-04-01 Almirall Prodesfarma Sa Derivados de 8-fenil-6,9-dihidro-(1,2,4,)triazolo(3,4-i)purin-5-ona.
US6555547B1 (en) 2000-02-28 2003-04-29 Cell Pathways, Inc. Method for treating a patient with neoplasia by treatment with a vinca alkaloid derivative
US6569638B1 (en) 2000-03-03 2003-05-27 Cell Pathways, Inc Method for screening compounds for the treatment of neoplasia
US6821978B2 (en) 2000-09-19 2004-11-23 Schering Corporation Xanthine phosphodiesterase V inhibitors
DE60226615D1 (OSRAM) * 2001-08-28 2008-06-26 Schering Corp
EP1790652A1 (en) * 2001-08-28 2007-05-30 Schering Corporation Polycyclic guanine phosphodiesterase V inhibitors
US20030211040A1 (en) 2001-08-31 2003-11-13 Paul Greengard Phosphodiesterase activity and regulation of phosphodiesterase 1B-mediated signaling in brain
EP1312363A1 (en) * 2001-09-28 2003-05-21 Pfizer Products Inc. Methods of treatment and kits comprising a growth hormone secretagogue
MXPA04004370A (es) * 2001-11-09 2004-08-11 Schering Corp Derivados policiclicos de guanina inhibidores de fosfodiesterasa v.
US7342884B2 (en) * 2002-03-13 2008-03-11 Harmonic, Inc. Method and apparatus for one directional communications in bidirectional communications channel
SI1509525T1 (sl) 2002-05-31 2006-12-31 Schering Corp Postopek priprave inhibitorjev ksantinske fosfodiesteraze V in njihovih prekurzorjev
PT1509525E (pt) * 2002-05-31 2006-12-29 Schering Corp Processo para preparação de xantinas inibidoras da fosfodiesterase v e de seus precursores
WO2005012303A1 (en) * 2003-07-31 2005-02-10 Schering Corporation Metabolite of xanthine phosphodiesterase 5 inhibitor and derivatives thereof useful for treatment of erectile dysfunction
AU2004260758B2 (en) * 2003-08-01 2007-06-07 Nippon Soda Co., Ltd. Phenylazole compounds, production process, and antioxidants
AU2004292991A1 (en) * 2003-11-21 2005-06-09 Schering Corporation Phosphodiesterase v inhibitor formulations
WO2006104870A2 (en) * 2005-03-25 2006-10-05 Schering Corporation Methods of treating benign prostatic hyperplasia or lower urinary track symptoms by using pde 5 inhibitors
WO2006133261A2 (en) * 2005-06-06 2006-12-14 Intra-Cellular Therapies, Inc. Organic compounds
EP1919287A4 (en) * 2005-08-23 2010-04-28 Intra Cellular Therapies Inc ORGANIC COMPOUNDS FOR TREATING A REDUCED DOPAMINE RECEPTOR SIGNALING ACTIVITY
AU2006313123B2 (en) * 2005-11-09 2012-01-12 Sagami Chemical Research Center Nucleic acid base having perfluoroalkyl group and method for producing the same
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2651519A1 (en) 2006-06-06 2007-12-13 Intra-Cellular Therapies, Inc. Organic compounds
WO2008063505A1 (en) 2006-11-13 2008-05-29 Intra-Cellular Therapies, Inc. Organic compounds
US9006258B2 (en) * 2006-12-05 2015-04-14 Intra-Cellular Therapies, Inc. Method of treating female sexual dysfunction with a PDE1 inhibitor
MX2010000098A (es) 2007-06-21 2010-04-21 Schering Corp Derivados de guanina policiclicos y sus metodos de uso.
US8846693B2 (en) * 2007-12-06 2014-09-30 Intra-Cellular Therapies, Inc. Optionally substituted pyrazolo[3,4-d]pyrimidine-4,6-diones
MX2010006212A (es) 2007-12-06 2010-08-10 Intra Cellular Therapies Inc Compuestos organicos.
JP5813511B2 (ja) 2008-12-06 2015-11-17 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
WO2010065148A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322905A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
KR20110095881A (ko) * 2008-12-06 2011-08-25 인트라-셀룰라 써래피스, 인코퍼레이티드. 유기 화합물
CA2740394A1 (en) * 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
AU2009322899A1 (en) 2008-12-06 2010-06-10 Intra-Cellular Therapies, Inc. Organic compounds
EP2400970A4 (en) 2009-02-25 2012-07-18 Intra Cellular Therapies Inc PDE-1-HEMMER FOR EYE DRESSING
WO2010103547A2 (en) * 2009-03-13 2010-09-16 Advinus Therapeutics Private Limited Substituted fused pyrimidine compounds
JP2012526810A (ja) 2009-05-13 2012-11-01 イントラ−セルラー・セラピーズ・インコーポレイテッド 有機化合物
SG10201507362TA (en) 2009-08-05 2015-10-29 Intra Cellular Therapies Inc Novel Regulatory Proteins And Inhibitors
WO2011081915A2 (en) * 2009-12-15 2011-07-07 Cebix Inc. Methods for treating erectile dysfunction in patients with insulin-dependent diabetes
JP5894148B2 (ja) 2010-05-31 2016-03-23 イントラ−セルラー・セラピーズ・インコーポレイテッドＩｎｔｒａ−Ｃｅｌｌｕｌａｒ Ｔｈｅｒａｐｉｅｓ， Ｉｎｃ． 有機化合物
EP2575817A4 (en) 2010-05-31 2014-01-08 Intra Cellular Therapies Inc ORGANIC CONNECTIONS
WO2011153138A1 (en) 2010-05-31 2011-12-08 Intra-Cellular Therapies, Inc. Organic compounds
TW201206937A (en) 2010-05-31 2012-02-16 Intra Cellular Therapies Inc Organic compounds
WO2012171016A1 (en) 2011-06-10 2012-12-13 Intra-Cellular Therapies, Inc. Organic compounds
US9801882B2 (en) 2013-02-17 2017-10-31 Intra-Cellular Therapies, Inc. Phosphodiesterase-1 inhibitors and their use in treatment of cardiovascular diseases
US9545406B2 (en) 2013-03-15 2017-01-17 Intra-Cellular Therapies, Inc. Method of treating a CNS injury with a PDE1 inhibitor
ES2836129T3 (es) 2013-03-15 2021-06-24 Intra Cellular Therapies Inc Compuestos orgánicos
EP3091983B1 (en) 2014-01-08 2019-10-02 Intra-Cellular Therapies, Inc. Pharmaceutical compositions comprising a pde-1 inhibitor and a pde-2 inhibitor
DK3157926T3 (da) 2014-06-20 2019-08-19 Intra Cellular Therapies Inc Organiske forbindelser
EP3177627B1 (en) 2014-08-07 2019-07-24 Intra-Cellular Therapies, Inc. Imidazo[1,2-a]-pyrazolo[4,3-e]-pyrimidin-4-one derivatives with pde1 inhibiting activity
US9546175B2 (en) 2014-08-07 2017-01-17 Intra-Cellular Therapies, Inc. Organic compounds
US10285992B2 (en) 2014-08-07 2019-05-14 Intra-Cellular Therapies, Inc. Combinations of PDE1 inhibitors and NEP inhibitors and associated methods
MX385382B (es) 2014-09-17 2025-03-18 Intra Cellular Therapies Inc Compuestos y metodos.
BR112017012005B1 (pt) 2014-12-06 2023-04-04 Intra-Cellular Therapies, Inc Compostos orgânicos inibidores de pde2, composições farmacêuticas compreendendo os ditos compostos e uso dos mesmos no tratamento de um distúrbio mediado por pde2
RU2709786C2 (ru) 2014-12-06 2019-12-20 Интра-Селлулар Терапиз, Инк. Органические соединения
EP3436083A4 (en) 2016-03-28 2019-11-27 Intra-Cellular Therapies, Inc. NOVEL COMPOSITIONS AND METHOD
WO2018049417A1 (en) 2016-09-12 2018-03-15 Intra-Cellular Therapies, Inc. Novel uses
EP3562828A1 (en) 2016-12-28 2019-11-06 Dart NeuroScience LLC Substituted pyrazolopyrimidinone compounds as pde2 inhibitors
EP3717488B1 (en) 2017-11-27 2021-09-29 Dart NeuroScience, LLC Substituted furanopyrimidine compounds as pde1 inhibitors
JP7401442B2 (ja) 2018-01-31 2023-12-19 イントラ－セルラー・セラピーズ・インコーポレイテッド 新規使用
EP4025202A4 (en) 2019-09-03 2023-08-02 Intra-Cellular Therapies, Inc. NOVEL CONNECTIONS
US12364695B2 (en) 2020-06-02 2025-07-22 Intra-Cellular Therapies, Inc. Methods of treating inflammatory disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE863525A (fr) * 1977-02-14 1978-07-31 Bristol Myers Co Heterocyclopyrimidines
CA1095906A (en) * 1977-02-14 1981-02-17 Davis L. Temple, Jr. Heterocyclopyrimidines, compositions and therapeutic process
ZA902282B (en) * 1989-03-29 1990-12-28 Merrell Dow Pharma Selective adenosine receptor compounds
US5064947A (en) * 1989-03-29 1991-11-12 Merrell Dow Pharmaceuticals Inc. Selective adenosine reseptor compounds
US5173492A (en) * 1989-09-14 1992-12-22 Kyowa Hakko Kogyo Co., Ltd. s-Triazolo(3,4-I)purine derivatives
ES2152207T3 (es) * 1989-10-20 2001-02-01 Kyowa Hakko Kogyo Kk Derivados condensados de la purina.

Also Published As

Publication number Publication date
DE69126980T2 (de) 1998-01-08
CZ281920B6 (cs) 1997-04-16
IL98559A0 (en) 1992-07-15
AU8199291A (en) 1992-01-07
NZ238609A (en) 1993-12-23
US5393755A (en) 1995-02-28
WO1991019717A1 (en) 1991-12-26
IE912126A1 (en) 1992-01-01
CZ374992A3 (en) 1993-10-13
CA2085733C (en) 1996-03-05
NO924940L (no) 1992-12-18
PL297299A1 (OSRAM) 1992-07-13
NO924940D0 (no) 1992-12-18
ATE155786T1 (de) 1997-08-15
JPH0747589B2 (ja) 1995-05-24
JPH05508647A (ja) 1993-12-02
HU9204032D0 (en) 1993-03-29
EP0538332A1 (en) 1993-04-28
DE69126980D1 (de) 1997-09-04
KR960004532B1 (ko) 1996-04-06
FI925731A0 (fi) 1992-12-17
ZA914727B (en) 1992-03-25
PL169481B1 (pl) 1996-07-31
OA09723A (en) 1993-08-30
RU2080322C1 (ru) 1997-05-27
EP0538332B1 (en) 1997-07-23
FI925731A7 (fi) 1992-12-17
AU651607B2 (en) 1994-07-28
CA2085733A1 (en) 1991-12-22
TW197441B (OSRAM) 1993-01-01

Similar Documents

Publication Publication Date Title
HUT65623A (en) Process for preparing polycyclic guanine derivatives and pharmaceutical preparations containing them
EP0730594B1 (en) 9-HYDROXY-PYRIDO [1,2-a]PYRIMIDIN-4-ONE ETHER DERIVATIVES
US7897607B2 (en) Cyclic compounds
EP2205241B1 (en) Polo-like kinase inhibitors
US6174884B1 (en) 1,5-dihydro-pyrazolo[34-D]-pyrimidinone derivatives
US6656935B2 (en) Aromatic nitrogen-containing 6-membered cyclic compounds
CN102292322B (zh) 用于治疗例如癌症的疾病的取代的嘧啶
AU2008249750B2 (en) Amino-heterocyclic compounds
EP1618107B1 (en) Condensed n-heterocyclic compounds and their use as crf receptor antagonists
EP3079700B1 (en) Soluble guanylate cyclase activators
AU2007337003B2 (en) MAPK/ERK kinase inhibitors
US20090247554A1 (en) Kinase inhibitors
PL162957B1 (pl) Sposób wytwarzania nowych pochodnych pirymidyny PL PL PL PL PL PL PL PL PL PL
CZ16796A3 (en) 2,8-disubstituted quinazolines, process of their preparation, pharmaceutical composition such compounds and their use
KR20080013886A (ko) 면역억제용 퓨린 및 이미다조피리딘 유도체
WO2007104053A2 (en) 8-heteroarylpurine mnk2 inhibitors for treating metabolic disorders
SK1302001A3 (en) SUBSTITUTED PYRAZOLE DERIVATIVES CONDENSED WITH SIX-MEMBEREDì (54) HETEROCYCLIC RINGS
JP2002523507A (ja) ジヒドロ−［１，２，３］トリアゾロ−［４，５−ｄ］ピリミジン−７−オン
EP3458063A1 (en) Methods for using triazolo-pyrazinyl soluble guanylate cyclase activators in fibrotic disorders
HU208824B (en) Process for the production of selestive adenozine antagonistic xantine derivatives and medical preparations containing them as active agents
US6306847B1 (en) Condensed purine derivatives
JP2003252875A (ja) 新規プリン誘導体
AU2011226819B2 (en) Amino-heterocyclic compounds
HK1145144B (en) Polo-like kinase inhibitors
CZ2001333A3 (cs) Substituované deriváty pyrazolu, způsob jejich výroby, léčiva tyto látky obsahující a jejich použití

Legal Events

Date Code Title Description
DFA9 Temporary protection cancelled due to abandonment